Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guang Lin

Showing results (501-510 of 502) with videos related to

Pageof 51
Sort By:
You have reached the last page of results.This site can display upto 502 results.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
Pageof 51

Showing results (501-510 of 502) with videos related to

Sort By:
Pageof 51
You have reached the last page of results.This site can display upto 502 results.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.
Pageof 51